Conference abstractPublished 25 Jul 2019
p53 R248Q mutation alters molecular trafficking and targeted drug responses in ovarian cancer
National Tsing Hua University, Taiwan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The dysfunction of tumor suppressor p53 and its regulators is a common feature of human cancer, including ovarian cancer. Specifically, the genetic alteration of p53 mutation is detected in up to 96% of high-grade serous ovarian carcinoma (HGSOC). Moreover, mutant p53 may cause oncogenic gain-of-function phenotypes under sustained activation of EGFR signaling. Thus, we aimed to investigate whether p53 mutation could affect combined inhibition of EGFR and the p53-specific ubiquitin ligase MDM2 in ovarian cancer. We selected p53 R248Q mutant, which has the highest mutation frequency in cancer, for this study. We found that, when p53 R248Q was transiently overexpressed, the p-AKT protein expression would increase significantly. Immunocytochemistry analysis further showed that, upon EGF stimulation or p53 R248Q mutant overexpression, several EGFR pathway and cross-talking mediators would translocate in unique patterns within the cell. Previously, we have demonstrated that combined inhibition of EGFR and MDM2 pathways by Gefitinib and JNJ exerts strong synergistic inhibition on p53-mutated HGSOC cells. Our immunofluorescence analysis revealed that, under such combined inhibition, the cytonuclear trafficking of these mediators would be disrupted. Moreover, when we compared the drug responses in different p53 status, we observed the sensitivity to single- or combined-inhibition treatments would be altered in p53 R248Q overexpressed cells. In summary, our findings suggest that p53 R248Q mutation might cause differential responses in signal transduction, molecular trafficking, and drug efficacy, which helps to advance our understanding in p53 signaling and cancer biology and to improve future therapeutic strategies on HGSOC.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Kai-Yun Tsai”
